NCT01513083View on ClinicalTrials.gov

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Breast Cancer
Interventions
DRUG

trastuzumab emtansine

Multiple intravenous doses

Trial Locations (13)

13273

Marseille

28007

Madrid

31059

Toulouse

33100

Udine

33905

Fort Myers

37203

Nashville

48201

Detroit

75231

Paris

88100

Catanzaro

97239

Portland

K1H8L6

Ottawa

M5G 2M9

Toronto

08003

Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01513083 - A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function | Biotech Hunter | Biotech Hunter